Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Korneuburg – page 37

860 clinical trials in Korneuburg, Austria across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Korneuburg at a glance
860
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

860 trials in Korneuburg

Open in trial search

Colitis ulcerative+1

Not recruiting

Study on the Long-Term Effects of TEV-48574 (Duvakitug) for Adults with Moderate to Severe Ulcerative Colitis or Crohn's Disease

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Systemic scleroderma

Not recruiting

Study on the Effects of Fipaxalparant in Patients with Diffuse Cutaneous Systemic Sclerosis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fipaxalparant
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Ovarian cancer

Not recruiting

Study on the Effectiveness of Durvalumab, Olaparib, and Bevacizumab in Patients with Newly Diagnosed Advanced Ovarian Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Astrazeneca AB

Study on BHV-7000 for Patients with Generalized Tonic-clonic Seizures in Idiopathic Generalized Epilepsy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Study on the Effectiveness and Safety of Polatuzumab Vedotin, Rituximab, and CHP in Patients with Untreated Diffuse Large B-Cell Lymphoma

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Polatuzumab Vedotin
  • Sponsor:F. Hoffmann-La Roche AG

Cardiac amyloidosis

Not recruiting

Study of Vutrisiran for Patients with Transthyretin Amyloidosis and Heart Disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Vutrisiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study on the Effects of Semaglutide in Patients with Early Alzheimer's Disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Study on the Effects of Zibotentan and Dapagliflozin in Patients with Chronic Kidney Disease and High Protein Levels

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Astrazeneca AB

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Rosnilimab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rosnilimab
  • Sponsor:Anaptysbio Inc.

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Dermatitis atopic

Not recruiting

Study of Baricitinib for Children and Adolescents with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Colitis ulcerative+1

Not recruiting

Study on the Effects of TEV-48574 for Adults with Moderate to Severe Ulcerative Colitis or Crohn's Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.